Combat Drugs shines on getting nod to divest Singapore subsidiary

06 Nov 2019 Evaluate

Combat Drugs is currently trading at Rs. 21.90, up by 1.00 points or 4.78% from its previous closing of Rs. 20.90 on the BSE.

The scrip opened at Rs. 21.05 and has touched a high and low of Rs. 21.90 and Rs. 19.95 respectively. So far 4741 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 30.40 on 14-Nov-2018 and a 52 week low of Rs. 16.20 on 19-Sep-2019.

Last one week high and low of the scrip stood at Rs. 21.90 and Rs. 19.80 respectively. The current market cap of the company is Rs. 17.52 crore.

The promoters holding in the company stood at 58.00%, while Institutions and Non-Institutions held 0.00% and 42.00% respectively.

Combat Drugs has received an approval for the full Disinvestment of the Fully Owned Subsidiary of the company in Singapore i.e. RA Labs by sale of entire Equity Shares held by the company, at cost, subject to shareholder approval and other statutory approvals, as applicable, if any. The Board of Directors of the company in their meeting approved the same.

Combat Drugs manufactures and markets pharmaceutical formulations in India. The company offers its products in various forms, such as tablets, capsules, liquid orals, and ointments.


Decipher Labs Share Price

12.00 -0.18 (-1.48%)
25-Apr-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1171.10
Cipla 1521.40
Lupin 2019.10
Zydus Lifesciences 859.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...